Skip to main content
Premium Trial:

Request an Annual Quote

Cequent to Receive European, Korean Patents on RNAi Technology

Premium

Cequent Pharmaceuticals said this week that it has received notices that the European Patent Office and the Korean Intellectual Property Office intend to grant patents covering the company's core RNAi technology.

The patent applications, entitled "Compositions for Bacterial-Mediated Gene Silencing and Methods Using the Same," relate to Cequent's so-called transkingdom RNAi technology, which involves using attenuated Escherichia coli to transcribe therapeutic shRNAs.

Specifically, the IP claims "attenuated bacteria as a therapeutic engine for the delivery of short interfering RNA molecules against disease-related genes, including cancer genes such as beta-catenin, whose up-regulation is implicated in the formation and proliferation of colorectal and other cancers," Cequent said.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.